Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,480,068 papers from all fields of science
Search
Sign In
Create Free Account
Fluzoparib
An orally available inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2, with potential antineoplastic activity. Upon oral administration…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
NCIt Antineoplastic Agent Terminology
PARP1 protein, human
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Jian‐ming Xu
,
Rongrui Liu
,
+15 authors
Quanren Wang
Journal of Clinical Oncology
2019
Corpus ID: 190862262
4060 Background: Fluzoparib (SHR3162) is an oral, selective PARP1 inhibitor. In our gastric cancer PDX model, fluzoparib…
Expand
2019
2019
Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer
N. Li
,
L. Wu
,
+16 authors
Q. Wang
Annals of Oncology
2019
Corpus ID: 208408740
Abstract Background Fluzoparib is a potent orally administered poly(ADP-ribose) polymerase (PARP) inhibitor. The safety and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE